Trump Administration Secures Major Drug Price Reduction Deal with AstraZeneca
President Trump announced a deal with AstraZeneca to lower drug prices for Americans, including "most-favored-nation" pricing for Medicaid and a $50 billion U.S. investment by 2030.
Overview
- President Trump announced a deal with AstraZeneca to significantly lower prescription drug costs for American consumers, especially Medicaid recipients, through major discounts.
- AstraZeneca agreed to a "most-favored-nation" pricing model, ensuring the U.S. pays competitive prices by matching the lowest prices offered in other developed nations.
- The company committed to a $50 billion investment in U.S. manufacturing, research, and development by 2030, including a new $4.5 billion plant near Charlottesville, Virginia.
- AstraZeneca will list primary care medications on the government website TrumpRx, allowing consumers to access popular drugs at significantly discounted prices directly.
- This agreement makes AstraZeneca the second drugmaker to partner with the Trump administration on drug price reductions, with advocates praising efforts to enhance affordable medication access.
Report issue
Read both sides in 5 minutes each day
Analysis
Center-leaning sources cover this story neutrally, focusing on reporting the facts of the Trump administration's deal with AstraZeneca to lower drug prices for Medicaid. They present the announcement, the terms of the agreement, and related developments like the new manufacturing plant and the TrumpRx.gov website without employing loaded language or taking an overt stance.
"AstraZeneca will charge most-favored-nation pricing to Medicaid, while guaranteeing such pricing on newly launched drugs, Trump said."
Chicago Tribune"AstraZeneca will offer its drugs to Medicaid patients at "most-favored-nation" prices, meaning the U.K.-based drugmaker will charge no more than the lowest rate offered in other high-income countries, Centers for Medicare and Medicaid Services Administrator Mehmet Oz said in a Friday afternoon Oval Office event."
CBS News"AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration."
ABC News"AstraZeneca will also offer discounts of up to 80% off list prices on direct sales to consumers."
NPR"AstraZeneca will charge most-favored-nation pricing to Medicaid, while guaranteeing such pricing on newly launched drugs, Trump said."
Associated Press"The deal is expected to include a "most favored nation" drug pricing model that would make prescriptions more affordable for low-income Americans, including those on Medicaid, the reports said."
USA TODAYArticles (12)
Center (6)
FAQ
The 'most-favored nation' (MFN) pricing model means AstraZeneca will match the lowest drug prices it offers in other developed countries for medications supplied to Medicaid in the U.S., ensuring competitive pricing.
AstraZeneca has committed to a $50 billion investment in U.S. manufacturing, research, and development by 2030, including building a new $4.5 billion manufacturing plant near Charlottesville, Virginia.
Medicaid recipients will benefit from major discounts on AstraZeneca drugs, with prices lowered to match those offered in other wealthy countries under the MFN pricing, significantly reducing their out-of-pocket costs.
TrumpRx is a government website where AstraZeneca will list primary care medications, allowing consumers to directly access popular drugs at significantly discounted prices under the new agreement.
AstraZeneca is the second drugmaker to partner with the Trump administration on drug price reductions, following Pfizer, signaling a growing effort to lower medication costs in the U.S.
History
- 1M
4 articles